- |||||||||| CN128 / Hangzhou Zede Pharma
Phase classification: Long-term Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Nov 22, 2023
P2, N=18, Completed,
Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Oct 2024 Phase classification: P2a --> P2
- |||||||||| CN128 / Hangzhou Zede Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Long-term Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Mar 6, 2023
P2a, N=18, Completed,
Phase classification: P2b --> P2 Active, not recruiting --> Completed | N=50 --> 18 | Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022
- |||||||||| CN128 / Hangzhou Zede Pharma
Enrollment closed, Trial primary completion date: Long-term Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Mar 18, 2022
P2a, N=50, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2022 --> Jun 2022
- |||||||||| CN128 / Hangzhou Zede Pharma
Journal: Effectiveness of the Iron Chelator CN128 in Mitigating the Formation of Dopamine Oxidation Products Associated with the Progression of Parkinson's Disease. (Pubmed Central) - Jun 22, 2021
CN128 is superior to DFP with regard to the reduction in formation of DAC and elevation in DA concentration. In summary, the results of this study suggest that prodromal application of the chelator CN128 could be effective in preventing the onset and slowing the early stage development of PD symptoms associated with oxidants and toxic intermediates resulting from the iron-mediated oxidation of the neurotransmitter dopamine with CN128 likely to be superior to DFP in view of its greater in vivo availability and less problematic side effects.
- |||||||||| CN128 / Hangzhou Zede Pharma
Journal: CN128, a new orally active hydroxypyridinone iron chelator. (Pubmed Central) - Sep 26, 2020
The Fe(III) affinity and metal selectivity of CN128 are similar to those of deferiprone, the logP value is more lipophilic, and its iron scavenging ability is superior. Overall, CN128 was demonstrated to be safe in a range of toxicity assessments and is now in clinical trials for the treatment of β-thalassemia after regular blood transfusion.
- |||||||||| CN128 / Hangzhou Zede Pharma
Trial completion date: Short-term Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Dec 19, 2019
P1, N=16, Completed,
Overall, CN128 was demonstrated to be safe in a range of toxicity assessments and is now in clinical trials for the treatment of β-thalassemia after regular blood transfusion. Trial completion date: May 2019 --> Dec 2019
- |||||||||| CN128 / Hangzhou Zede Pharma
Trial completion, Enrollment change: Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Dec 19, 2019
P1, N=32, Completed,
Trial completion date: May 2019 --> Dec 2019 Recruiting --> Completed | N=47 --> 32
- |||||||||| CN128 / Hangzhou Zede Pharma
Trial completion, Trial completion date: Short-term Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Aug 7, 2019
P1, N=16, Completed,
Recruiting --> Completed | N=47 --> 32 Recruiting --> Completed | Trial completion date: Dec 2019 --> May 2019
- |||||||||| CN128 / Hangzhou Zede Pharma
Trial completion date: Clinical Study of CN128 in Thalassemia Patients (clinicaltrials.gov) - Apr 17, 2019
P1, N=47, Recruiting,
Recruiting --> Completed | Trial completion date: Dec 2019 --> May 2019 Trial completion date: Dec 2018 --> Dec 2019
|
